UK-based artificial intelligence drug design and development company Isomorphic Labs has secured $2.1 billion (€1.94 billion) in Series B funding to accelerate its transition from developing innovative AI models to deploying them at larger scale across its therapeutic pipeline, according to Pharmaceutical Technology.

The round was led by Thrive Capital, with participation from existing investors Alphabet and GV, and new investors CapitalG, MGX, Temasek, and the UK Sovereign AI Fund, significantly broadening Isomorphic Labs' global capital base.

Max Jaderberg, president of Isomorphic Labs, said: "This milestone is built on the strength of our AI drug design engine, which has already proven its worth across our internal programmes by hitting key milestones and identifying viable candidates with unprecedented speed. Our drug design engine works, and it's giving us a repeatable way to design new medicines for a wide range of diseases, building a future of medicine that was previously out of reach."

Proceeds will be deployed to further develop and scale IsoDDE, Isomorphic Labs' unified AI drug design engine, accelerate its pipeline of therapeutic programmes toward clinical stages, and support hiring across AI, clinical talent, drug design, and engineering functions at all sites.

IsoDDE integrates several breakthrough AI models supporting work across multiple therapeutic areas and drug modalities, with recently published findings highlighting its predictive performance and expanding capabilities in structure prediction and real-world drug discovery.

Strategic collaborations with Novartis, Johnson & Johnson, and Eli Lilly validate Isomorphic Labs' AI-driven approach and its contribution to pharmaceutical development pipelines.

The funding positions Isomorphic Labs to expand both its geographic reach and scientific capabilities as it seeks to address complex biological and medical challenges on a global scale.

Access the full report for comprehensive details on the Isomorphic Labs Series B funding and IsoDDE platform.